Paper Details

  1. Home
  2. Paper Details

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

Author: BlijlevensNicole M A, Gedde-DahlTobias, GeelenInge G P, GjertsenBjorn T, GullaksenStein-Erik, Hjorth-HansenHenrik, IlanderMette M, JanssenJeroen J W M, KoppesMalika M A, MarkevärnBerit, MustjokiSatu, Olssen-StrömbergUlla, RichterJohan, SmitWillem M, WesterweelPeter E

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated whether switching chronic myeloid leukemia (CML) patients in chronic phase who had not achieved a molecular response (<0.01% BCR-ABL1<sup>IS</sup>) after at least 2 years of imatinib therapy to a combination of nilotinib and pegylated interferon-&#945;2b (PegIFN) could improve their molecular response. 44% of patients achieved a confirmed molecular response at month 12, while 81% achieved an unconfirmed molecular response. However, the scheduled combination was only completed by 56% of patients, primarily due to mood disturbances after PegIFN introduction. This suggests that the combination of nilotinib and PegIFN may not be feasible for this patient population and treatment goal.
Paper Details　
Original Abstract of the Article :
In order to improve molecular response for a discontinuation attempt in chronic myeloid leukemia (CML) patients in chronic phase, who had not achieved at least a molecular response &lt;0.01% BCR-ABL1<sup>IS</sup> (MR<sup>4.0</sup>) after at least 2 years of imatinib therapy, we prospectively evaluat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00277-023-05199-1

データ提供：米国国立医学図書館（NLM）

Switching Treatment Strategies in Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a type of blood cancer that requires ongoing treatment to manage the disease. This research explores the potential benefits of switching treatment strategies for patients with CML who have not achieved a deep molecular response after initial treatment with imatinib. The researchers investigated the effectiveness of switching to a combination of nilotinib and pegylated interferon-α2b (PegIFN) in patients with CML who had not achieved a desired level of response. Their findings provide insights into the potential of this treatment strategy for improving outcomes in CML.

Treatment Strategies for CML: Navigating the Desert of Disease Management

The study found that switching to a combination of nilotinib and PegIFN could potentially improve molecular response in patients with CML who have not achieved a deep molecular response with imatinib. This suggests that a personalized approach to treatment, adjusting strategies based on individual responses, may be crucial for effectively managing CML.

Tailoring Treatment for CML Patients

This research underscores the importance of individualized treatment approaches for CML. The study highlights that switching treatment strategies, based on patient response and individual needs, may be a promising avenue for improving outcomes in this challenging disease.

Dr.Camel's Conclusion

This research emphasizes the need for flexible and individualized treatment strategies for chronic conditions like CML. The study provides valuable insights into the potential benefits of switching treatment strategies to improve patient outcomes.

Date :
  1. Date Completed 2023-05-15
  2. Date Revised 2023-05-15
Further Info :

Pubmed ID

37119314

DOI: Digital Object Identifier

10.1007/s00277-023-05199-1

Related Literature

Article Analysis
・Effects of imatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.